--- title: "Artivion, Inc. (AORT.US)" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/AORT.US.md" symbol: "AORT.US" name: "Artivion, Inc." industry: "Health Care Equipment" datetime: "2026-05-20T16:07:27.574Z" locales: - [en](https://longbridge.com/en/quote/AORT.US.md) - [zh-CN](https://longbridge.com/zh-CN/quote/AORT.US.md) - [zh-HK](https://longbridge.com/zh-HK/quote/AORT.US.md) --- # Artivion, Inc. (AORT.US) ## Company Overview Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries. | Item | Detail | |------|--------| | Industry | Health Care Equipment | | Exchange | US Market | | Website | [artivion.com](https://artivion.com) | ## Key Drivers > *AI-analyzed key factors driving this stock's performance* ## Longbridge Financial Score™: B > *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge* > Updated: 2026-05-20T04:30:13.000Z **Overall: B (0.35)** **Industry**: Health Care Equipment | Metric | Value | |--------|-------| | Industry Ranking | 26 / 183 | | Industry Median | C | | Industry Average | C | - **Style**: Blend - Stocks in which the company has both growth and mature businesses. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. **Multi Score**: B #### Style Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | 17.59% | | | Net Profit YoY | 154.69% | | | P/B Ratio | 2.45 | | | Dividend Ratio | 0.00% | | #### Size Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 1103390345.50 | | | Revenue | 458689000.00 | | #### Multi Score Score: B | Indicator | Value | Rating | |-----------|-------|--------| | ROE | 3.14% | C | | Profit Margin | 2.55% | C | | Gross Margin | 64.85% | A | | Revenue YoY | 17.59% | B | | Net Profit YoY | 154.69% | A | | Total Assets YoY | 11.63% | B | | Net Assets YoY | 53.09% | A | | Cash Flow Margin | 496.59% | A | | OCF YoY | 17.59% | B | | Turnover | 0.55 | C | | Gearing Ratio | 48.99% | C | ```chart-data:radar { "title": "Longbridge Financial Score - Artivion, Inc.", "chart_type": "radar", "dimensions": [ { "name": "Style Score", "grade": "", "indicators": [ { "name": "Revenue YoY", "value": "17.59%", "rating": "" }, { "name": "Net Profit YoY", "value": "154.69%", "rating": "" }, { "name": "P/B Ratio", "value": "2.45", "rating": "" }, { "name": "Dividend Ratio", "value": "0.00%", "rating": "" } ] }, { "name": "Size Score", "grade": "", "indicators": [ { "name": "Market Cap", "value": "1103390345.50", "rating": "" }, { "name": "Revenue", "value": "458689000.00", "rating": "" } ] }, { "name": "Multi Score", "grade": "B", "indicators": [ { "name": "ROE", "value": "3.14%", "rating": "C" }, { "name": "Profit Margin", "value": "2.55%", "rating": "C" }, { "name": "Gross Margin", "value": "64.85%", "rating": "A" }, { "name": "Revenue YoY", "value": "17.59%", "rating": "B" }, { "name": "Net Profit YoY", "value": "154.69%", "rating": "A" }, { "name": "Total Assets YoY", "value": "11.63%", "rating": "B" }, { "name": "Net Assets YoY", "value": "53.09%", "rating": "A" }, { "name": "Cash Flow Margin", "value": "496.59%", "rating": "A" }, { "name": "OCF YoY", "value": "17.59%", "rating": "B" }, { "name": "Turnover", "value": "0.55", "rating": "C" }, { "name": "Gearing Ratio", "value": "48.99%", "rating": "C" } ] } ] } ``` ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | 94.49 | 43/183 | 186.24 | 179.23 | 172.62 | | PB | 2.45 | 65/183 | 4.94 | 4.67 | 4.01 | | PS (TTM) | 2.41 | 57/183 | 5.06 | 4.49 | 3.74 | | Dividend Yield | 0.00% | - | - | - | - | ## Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | | --- | --- | --- | --- | --- | --- | --- | --- | | 01 | Delcath (DCTH.US) | C | A | B | A | A | A | | 02 | Electromed (ELMD.US) | A | B | A | A | B | A | | 03 | Intuitive Surgical (ISRG.US) | A | B | C | A | B | B | | 04 | Stryker (SYK.US) | A | C | C | C | B | B | | 05 | Boston Scientific (BSX.US) | A | B | C | C | B | B | ## Institutional View ### Analyst Rating Distribution > As of 2026-05-20T04:00:00.000Z Total Analysts: **7** | Rating | Count | Percentage | |--------|-------|-----------| | Buy | 6 | 86% | | Overweight | 1 | 14% | ### Target Price Forecast | Metric | Price | |--------|-------| | Current Price | 22.36 | | Highest Target | 58.00 | | Lowest Target | 42.00 | ## References - [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/AORT.US/overview.md) - [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/AORT.US/norm.md) - [Related News](https://longbridge.com/en/quote/AORT.US/news.md) - [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/AORT.US/filings.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**